7月22日,业聚医疗(06929)发布公告,公司于日本开展的关键性临床试验(OM-0031)已完成首例患者入组。 本次试验将评估公司自主研发的冠状动脉紫杉醇药物涂层球囊,标志着公司凭借多元化产品组合,巩固于日本介入心脏病学市场领导地位的重要一步。 公告提到,这项OM-0031临床试验是一项前瞻性、多中心合作研究,旨在严谨评估药物涂层球囊的安全性及有效性。试验对象为冠状动脉疾病患者,特别针对小...
Source Link7月22日,业聚医疗(06929)发布公告,公司于日本开展的关键性临床试验(OM-0031)已完成首例患者入组。 本次试验将评估公司自主研发的冠状动脉紫杉醇药物涂层球囊,标志着公司凭借多元化产品组合,巩固于日本介入心脏病学市场领导地位的重要一步。 公告提到,这项OM-0031临床试验是一项前瞻性、多中心合作研究,旨在严谨评估药物涂层球囊的安全性及有效性。试验对象为冠状动脉疾病患者,特别针对小...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.